ADAM10 and Alzheimer disease: We have previously shown that astrocytic Ca2+signaling in AD is altered using a variety of protocols/models usually employed for neuronal evaluation, including Aβ oligomer treatment32, an uncoupling peptide of ADAM10 and SAP9733, or triple transgenic mice34.